The molecular and cellular basis of inflammation has become a topic of great interest of late because of the association between mechanisms of inflammation and risk for cancer. Inflammatory-mediated events, such as the production of reactive oxygen species (ROS), the activation of growth factors (for wound repair), and the altering of signaltransduction processes to activate cell-proliferation (to replace necrotic/apoptotic tissue cells), events that also can occur independently of inflammation, are all considered to be components of risk for a variety of cancers. Using scar cancer of the lung as an example, mechanisms of inflammation associated with recurring infections with Mycobacterium tuberculosis are discussed in the context that they may, in fact, be the major or sole cause of a cancer. Production of ROS, prostaglandins, leukotrienes, and cytokines in pulmonary tissues is greatly enhanced due to a cell-mediated immune response against macrophages infected with M. tuberculosis. These responses lead to the extensive fibrosis associated with recurring infections, possibly leading to decreased clearance of lymph and lymph-associated particles from the infected region. They also will enhance rates of cell division by inhibiting synthesis of P21, leading to enhanced progression from G0 arrest to G1 phase, from G1 to S phase, and from G2 to M phase of the cell cycle. By increasing rates of oxidative DNA damage and inhibiting apoptosis by enhancing synthesis of BCL-2, mutagenesis of progeny cells is enhanced, and these effects coupled with enhanced angiogenesis stimulated by COX-2 products lead to an environment that is highly conducive to tumorigenesis. Based on the evidence, it appears that but for an inflammatory response to recurring infections, some cases of scar cancer would not exist. By making appropriate lifestyle and dietary changes, a variety of anti-inflammatory effects can be produced, which should attenuate inflammation-induced risk for cancer.
The purpose of this review is to illustrate from a mechanistic standpoint that inflammatory processes may be very important risk factors for pulmonary cancers, with scar cancers of the lung being a relatively highincidence example of this risk. Although scar cancers of the lung have been recognized for several decades, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] a direct mechanistic association between the scar itself and the tumor has not been documented. Because no direct evidence has been observed for a causal association between the presence of scar tissue and cancer, several relatively recent publications have refuted the concept that pulmonary scars can be causal in lung cancer. [1] [2] [3] [4] [5] To discern cause, however, one must know the relative time course and the (integrated) mechanisms of the two events. By using clinical data (tissue pathology/histology), which are obtained long after the events leading to the scar or cancer formation have occurred, it is often difficult to sort out any definitive time sequence between the initiation of the processes resulting in scar formation and the subsequent development of the tumor. In spite of these limitations, in some reports there is evidence that the scar (and scarring process) predates the tumor, [6] [7] [8] [9] [10] [11] in others it is impossible to tell, 12, 13 and in others there is evidence that there was an active scarring process as a result of the tumor. 2, 3, 5, [14] [15] [16] The basic assumption behind any conclusions of no association between a pulmonary scar and its "associated" tumor [1] [2] [3] [4] [5] is that the scar itself cannot have directly caused the tumor. In one article, 4 the authors even ruled out tuberculosis as a contributing cause even though 10 of 49 cancer patients had tuberculosis that predated the cancer. The basis of their argument was that the actual scar tissue resulting from the tuberculosis infection was not a component of the lung tumor itself. In no case did any of the authors discuss the process of inflammation that can lead to scar formation as a contributing cause for the scar-associated cancer. This was unfortunate because the 2 events, scar formation and carcinogenesis, may actually be highly associated due to a common cause for both. The possibility exists that the chronic inflammation due to the tuberculosis infection 4 may have led to development of the cancer (see below), and it is certainly possible that the region of scar formation may actually be smaller than the region of inflammation. In more general terms, it may be no coincidence that either a variety of pulmonary infections or mineral deposits in the lungs were regarded as the most likely damaging agents leading to inflammation and scar formation in those reports that had evidence that scar formation predated the lung cancers. [6] [7] [8] [9] 11 Inflammatory processes in response to those agents (leading to scarring) could very likely have been one of the predominant mechanistic causes of the lung cancers as well.
Lung cancers that occur in association with scars are not that uncommon. They increased in incidence from 2% between 1955 and 1959 to approximately 16% of the tumors (out of 1,186 lung cancer cases) between 1970 and 1975, with no relationship between smoking habits and scar cancer observed. 17 This lack of association between smoking and scar cancer is an important point because it indicates that chronic inflammation may work, in part, through mechanisms that are independent of those common to smokingassociated cancers. In the only molecular-based study found that compared scar-and non-scar-associated cancers, 18 the scar cancers were more often ERBB-2 negative and k-ras (codon 12) positive, whereas the non-scar-associated cancers were ERBB-2 positive and k-ras negative, indicating a divergent etiology between the 2 types of cancer. Mutations in k-ras at codon 12 have been observed in the neogenic epithelia of cases with pulmonary interstitial pneumonia 19 and atypical alveolar hyperplasia, 20 indicating that the G to A transitions were most likely due to the inflammatoryinduced repair process and that the k-ras mutation may be an early event in lung carcinogenesis.
In those patients with idiopathic pulmonary fibrosis, [21] [22] [23] the incidence of lung cancer is much higher than in the general population-as high as 13% to 15%. 21, 22 Although the primary cause of idiopathic fibrosis is unknown, the fibrotic process is clearly due to an ongoing and chronic inflammatory response. [24] [25] [26] [27] [28] [29] Fibrosis is characterized by some form of inflammatory disease with alteration of normal tissue architecture and the accumulation of mesenchymal cells, which replace normal tissue cells. [24] [25] [26] The fibrosis appears to be initiated through some type of tissue injury followed by a chronic inflammatory response involving a variety of cytokines: IL-1, IL-8, TNF-α, monocyte chemotactic protein-1, platelet-derived growth factor, insulin-like growth factor, transforminggrowth factor-β, and the collagen-binding heat-shock protein 47. [25] [26] [27] [28] [29] In fibrosis cases where the inflammation is due to infection or damage, the same sequelae of inflammatory events occurs, [30] [31] [32] indicating that regardless of the primary cause, chronic inflammatory mechanisms are responsible for the resulting fibrosis. Thus, because there is a higher incidence of lung cancer in populations with chronic inflammatory disease regardless of cause (see above), it is reasonable to conclude that the process of inflammation that leads to the scarring also may be responsible for creating the additional risk for carcinogenesis.
Mechanisms of Inflammation and Carcinogenesis
Inflammatory-related risk for carcinogenesis may be due in a large part to an enhanced production of reactive oxygen species (ROS) (leading to DNA mutations), to altered activation of cell cycle-related signal transduction pathways, and to fibrotic-related changes in lymph circulation. How the risk develops, however, is a very complex process. Briefly, an inflammatory process is initiated by either infection, cellular damage, or the production of ROS, which then stimulate the synthesis (and secretion) of IL-1, IL-6, and TNF (predominantly) by macrophages as well as endothelial cells. [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] These are, in part, responsible for the expression of the acute-phase inflammatory response elements: cyclooxygenase-2 (COX-2), IL-8, NFκβ and c-reactive protein. [36] [37] [38] IL-6, TNF, and NFκβ are in turn associated with inducing the synthesis of Pselectin, E-selectin, VCAM, and ICAM by endothelial cells. 33, 35, 41 These molecules are necessary for the recruitment of more leukocytes into the infected or damaged area and for activating the leukocytes. Activated leukocytes produce large quantities of ROS such as superoxide and hydrogen peroxide, which react with each other to produce the highly reactive (and damaging) hydroxyl radical. These reactive compounds are responsible for killing the infective agents. Unfortunately, they also cause oxidative damage to surrounding cells and create an enhanced risk for inflammation-mediated cytotoxicity and DNA damage in the normal cells in the inflamed region.
The other aspect of an inflammatory reaction that is important is the production of prostaglandins and leukotrienes from arachidonic acid. The enzyme phospholipase A2 can be activated by ROS or calcium. [44] [45] [46] [47] [48] [49] Once activated, phospholipase A2 cleaves arachidonic acid from cellular membrane phospholipids. The arachidonic acid is a substrate for the enzymes cyclooxygenase (COX, constitutively expressed) and COX-2 (induced by inflammatory cytokines; see above), leading to enhanced synthesis and release of prostaglandins and leukotrienes. These vasoactive products are responsible for increasing the amount of local vasodilation and vasopermeability to greatly enhance the accumulation of leukocytes within the inflammatory area. In addition to their vasoactive activities, COX-2 produces prostaglandins, which inhibit apoptosis and stimulate angiogenesis and invasiveness. 50 The importance of oxygen radicals generated by activated leukocytes cannot be overemphasized. ROS are implicated as part of the mechanism for many cancers. [51] [52] [53] When the rate of cell division exceeds the rate at which ROS-mediated DNA damage can be repaired, the rate at which mutations form is increased and the risk for cancer increases. 51 The rate of ROS-mediated DNA-adduct formation can be as great as 10,000 lesions per cell each day from endogenous sources. 52 Even in tobacco-associated cancers, ROS play a very important role. 8-Hydroxy-deoxyguanosine (8-OH-dG), a hydroxyl radical-caused DNA adduct, is elevated in mice treated with the tobacco-specific carcinogen 4-(methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) while the consumption of (-)-epigallocatechin gallate (EGCG), a potent antioxidant found in green tea, significantly lowers levels of 8-OH-dG in lung DNA and decreases incidence of cancer in NNKtreated animals. 53 Thus, ROS derived from inflammatory reactions are a component of endogenous carcinogenic risk, a risk that is greatly elevated during conditions of longterm chronic inflammation due to infection or mineral deposition. As a result of chronic inflammation, the constant exposure to COX-2-derived prostaglandins also would enhance risk for carcinogenesis by reducing apoptosis and increasing the likelihood of mutant cells surviving to produce cancer cells. In the event that a cancer develops under these conditions, then the COX-2-derived prostaglandins would enhance growth through the stimulation of angiogenesis and enhanced invasiveness.
In addition to causing DNA damage, oxygen radicals also are capable of altering normal signaltransduction pathways in the cell. ROS produced through inflammatory mechanisms are able to directly activate the oncogenes jun and fos. ROS are involved as secondary messengers in the activation of PKC-mediated signaling pathways, which transduce signals from the cell membrane to the nucleus. 54, 55 ROS also are able to directly activate PKC. 56 Inhibitors of PKC, such as calphostin C, prevent oxidant-mediated induction of c-fos. 57 The DNA binding activity of c-jun also is positively regulated by PKC-dependent dephosphorylation. 58 Following activation of PKC, the c-jun/c-fos heterodimer (AP-1) binds to the antioxidant response element (ARE) and enhances transcription of a variety of proteins. Overexpression of jun has been associated with lung cancer [59] [60] [61] [62] [63] and provides evidence of another mechanism through which inflammatory mechanisms contribute to a greater risk for cancer.
Tuberculosis Infection as Cause for Scar Cancer
Using infection with Mycobacterium tuberculosis as an example, the following sequence of events (please see Figure 1 ) illustrates the potential for the previously discussed inflammatory mechanisms to be causal in pulmonary carcinogenesis. Because no single experiment has addressed every possible biological result of infection with M. tuberculosis in humans, the illustrated pathways comprise a hypothetical construct based on a composite of both in vitro and in vivo research involving a variety of cell types (as referenced). Initial exposure to M. tuberculosis would lead to phagocytosis of the majority of the mycobacteria in the alveoli by alveolar macrophages as well as phagocytosis of any mycobacteria that penetrate the alveolar epithelium by interstitial macrophages. 6 4 The activated macrophages would then secrete reactive oxygen species, nitric oxides, and inflammatory cytokines, with the alveolar macrophages secreting more of the radical molecules and TNF and the interstitial macrophages releasing more of the inflammatory cytokines Il-1 and IL-6. 65 ROS attack on membrane lipids of both epithelial and endothelial cells leads to calcium and ROS entry into the cell. The calcium and ROS activate phospholipase A-2, [44] [45] [46] [47] which releases arachidonic acid from the cell membrane, and a variety of vasoactive prostaglandins, thromboxanes, and leukotrienes are then produced by the cyclooxygenase and lipoxygenase enzymes leading to vasodilation and vasopermeability. The release of ROS by alveolar macrophages also would enhance the amount of oxidative damage to DNA in the epithelial cells, leading to a source of increased risk for carcinogenesis. The IL-1, IL-6, and TNF bind to receptors on the pulmonary epithelial cells and on the vascular endothelial cells leading to the production of the chemoattractant molecules P-selectin, E-selectin, VCAM, and ICAM. 33, 35, 41 The prostaglandin-mediated vasodilation and enhanced vasopermeability combined with the synthesis of adhesion molecules leads to an accumulation of activated neutrophils, macrophages, lymphocytes, and monocytes in the tissue.
The activation of alveolar and interstitial macrophages (and the resulting ROS and cytokine release) by the initial infection is relatively weak and is due predominantly to the phagocytic activity-mediated activation of the macrophages. This is because M. tuberculosis does not secrete toxins or produce an LPSstimulated inflammatory response. [66] [67] [68] In addition, M. tuberculosis is very resistant to digestion by macrophages and lives quite well inside them, providing a ready reservoir of living mycobacteria for continuing the infection. Enhanced activation of the ROS and cytokine release and phagocytic activities occur when cell-mediated immune responses develop after several weeks (or even months). Some of the macrophages that ingest the mycobacteria migrate to the lymph and 
Other involved cells and structures include capillaries (C) and capillary endothelial cells (EN), lymphatic ducts (L) and lympathatic endothelial cells (EN), stem cells (S), neutrophils (N), pulmonary epithelial cells (EP), and T cells (T). B. Pulmonary epithelial cells, vascular endothelial cells, and fibroblasts respond to the cytokines and ROS by synthesizing cellular adhesion molecules and vasoactive prostaglandins and leukotrienes. Macrophages with ingested mycobacteria
migrate to the lymph, interact with T cells, and initiate cell-mediated immunity against the mycobacteria. C. A full-blown inflammatory attack on the mycobacteria is initiated with recruitment of large numbers of neutrophils and macrophages. In response to the large increase in ROS and cytokine release, collagen production by fibroblasts and fibrinogen production by epithelial cells is greatly stimulated and COX-2 enzymes are induced. Cellular damage by ROS leads to cellular necrosis, DNA damage, and activation of AP-1, whereas T-cell activation of macrophages leads to their death by apoptosis. D. A fibrotic granuloma is formed from the necrotic cells, apoptotic cells, and living macrophages (infected with the mycobacteria) when they are encapsulated by the fibrotic process. The granuloma effectively walls off the infected macrophages (and dead/dying cells) from the healthy tissue and prevents further inflammatory responses to the mycobacteria. Scarring also interferes with lymph flow, decreasing removal of large cellular debris. Stem cells in the area proliferate in response to the cellular necrosis to replace the destroyed pulmonary cells. E. An outbreak of mycobacteria from the granuloma stimulates another cycle of cell-mediated inflammatory response, leading to much greater ROS and cytokine production with more extensive cellular responses including greater DNA damage, more extensive necrosis, additional scarring, and enhanced cell division via AP-1 activation in an attempt to replace the dead cells. F. With repeated cycles of recurring infections, sufficient numbers of DNA mutations arise in the proliferating cells to lead to transformation into cancer cells (C).
(continued)
activate T-lymphocytes, which then differentiate and proliferate into antigen-specific memory T cells. Following contact with sensitized T cells, macrophages are activated to a high degree to secrete ROS and proinflammatory cytokines, resulting in a "full-blown" inflammatory response. This response produces a large increase in ROS and cytokine secretion, leading to the accumulation of large numbers of neutrophils and macrophages in the tissue and further increases in ROS and cytokine production. In addition, contact with sensitized T cells induces apoptosis of the infected macrophages, and it is this process of (macrophage) apoptosis that effectively kills the mycobacteria via the DNAses produced during this process. [66] [67] [68] The enhanced production of the cytokines TNFα and IL-1 by the macrophages going through apoptosis 69, 70 induces the expression of COX-2 in tissue macrophages, fibroblasts, endothelial, and epithelial cells, 36, 71, 72 which further enhances prostaglandin release, greatly increasing the efficiency of the inflammatory response cycle.
The large amounts of ROS generated during an active infectious inflammatory response would then be responsible for causing greater than normal amounts of DNA damage, leading to increased risk for cancer through enhanced rates of DNA damage. In addition, the enhanced production of ROS increases the activation of molecular pathways, leading to enhanced DNA-binding of the oncogenes jun and fos. [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] Activation of jun/fos (AP-1) appears to lead to enhanced rates of cell proliferation by inhibiting expression of P21, leading to release from G2/M arrest and progression into mitosis. 73, 74 P21 also binds to cyclin-dependent kinases responsible for inhibiting progression from G0 arrest into G1 as well as progression from G1 to S phase. 75 These effects on cell cycle will not only enhance rates of cell division and reduce time for DNA-repair but also reduce the time for initiating apoptosis in those dividing cells that have DNA damage and existing mutations, thus greatly enhancing the risk for accumulating carcinogenic mutations in progeny cells.
In addition to the inflammation-inducing vasoactive effects (discussed above), recent evidence indicates that induction of COX-2 enhances tumor formation by enhancing angiogenesis and attenuating apoptosis. In a variety of human tumors, both epithelial cells and tumor cells express COX-2, and the COX-2 expression is associated with suppression of apoptosis and increased growth of intratumoral blood vessels. 50, 76, 77 Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGFβ) not only appear to be important growth factors for angiogenesis, they also coexpress with COX-2 in malignant and nonmalignant tissues. Angiogenesis in these tissues also appears to be associated with enhanced production of PGE2 by COX-2. 76, 77 Thus, growth of existing (or developing) tumors also may be enhanced via a prolonged or chronic inflammatory process.
Decreasing rates of apoptosis are apparently related to enhanced synthesis of BCL-2, which appears to be mediated by PGE-2 produced by COX-2. 78, 79 Enhanced BCL-2 inhibits the cytochrome c-mediated pathway of apoptosis, resulting in greater numbers of cells that contain DNA damage and DNA mutations progressing into mitosis, thus again increasing risk for cancer.
All of the events discussed above that are associated with a tuberculosis infection clearly could greatly increase risk for cancer by increasing DNA damage, inhibiting apoptosis, increasing rates of cell-division, and enhancing angiogenesis. Following an initial infection with M. tuberculosis, the T-cell mediated apoptosis of macrophages (and surrounding tissue cells) initiates the formation of fibrotic granulomas within the lung at the site of the infection. The enhanced formation of scar tissue is predominantly due to enhanced collagen synthesis by pulmonary fibroblasts mediated by induction of HSP47, 29, 80 the induction of which is mediated by TGFβ and IL-1β expressed by stimulated macrophages. IL-6, also produced by the stimulated macrophages and neutrophils, will stimulate synthesis of fibrinogen by both hepatocytes and pulmonary epithelial cells. 81 The enhanced fibrinogen availability contributes to the fibrosis resulting from the TGFβ/IL-1β stimulation. Thus, the fibrosis associated with tuberculosis infection is a result of expression of acute-phase proteins resulting from the inflammatory process.
The fibrotic granulomas (which contain T cells, infected macrophages, apoptotic macrophages and neutrophils, and necrotic macrophages, neutrophils, endothelial cells, and fibroblasts killed by ROS) essentially contain the infection, and only when the bacilli break out of the granuloma will a recurrence of the infection occur. [68] [69] [70] [71] With a poorly developed cellmediated immune response to the mycobacteria, repeated recurrences of active disease will lead to progressive destruction of the lung through extensive inflammatory-mediated stimulation of fibrosis. Repeated inflammatory responses to each recurrence will therefore enhance risk for cancer each time as well, with greater cumulative risks associated with more extensive and more frequent recurrences. As the area of fibrosis becomes more extensive, the risks for cancer associated with poor lymph drainage in these fibrotic areas also would be enhanced.
In summary, cytokines, prostaglandins, and leukotrienes, which are produced in response to infection and cellular damage, activate neutrophils and macrophages to accumulate in the infected area. The recruited cells then produce ROS (and additional cytokines) in an attempt to kill off the infectious agent. With chronic unresolved inflammation, extensive tissue fibrosis occurs with concomitant changes in organ function and morphology. Along with the chronic inflammation comes a greatly enhanced risk for cancer arising from enhanced ROS production leading to DNA mutations, inhibited apoptosis, and enhanced signal transduction, leading to activation of oncogenes. Blocked lymphatic flow also contributes to enhanced risk for cancer through delaying clearance of activated leukocytes as well as increasing the probability for the deposition of metastatic cells within the fibrotic area.
Implications
The recognition that inflammatory processes are significant factors in carcinogenesis is important because preventive measures that target these processes are already available and could be used to provide immediate reductions in risk if adopted for this purpose. In a
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noninflammatory model of carcinogenesis 82 and a human epidemiology study, 83 the use of inflammation inhibitors was documented to significantly reduce cancer. When both an antioxidant and cyclooxygenase-2 inhibitors are used, positive additive effects are observed, indicating the possibility that each preventive agent works through a different contributing mechanism. 84, 85 Thus, both antioxidants and COX-2 inhibitors reduce cancer in animal models through additive mechanisms, whereas epidemiological studies indicate very strong biological relevance to both of these mechanisms in humans. Because of the relatively high risk for lung cancer associated with exposure to mineral dusts and pulmonary infections, prophylactic preventive measures may be recommended for exposed individuals. In addition to chemo-preventive methods using anti-inflammatory drugs, 82, 84, 85 dietary and physical activity modifications also may be important. Consumption of omega-3 fatty acids (eg, EPA) in fish oils is known to decrease inflammatory responses to a variety of stimuli. As extensively reviewed by others, 50,86 the omega-3 fatty acids compete with arachidonic acid and greatly reduce the production of PGE2 and leukotriene B4 and enhance production of LTB5, which is much less potent than LTB4 in chemotactic activity, greatly reducing adhesion of peripheral blood leukocytes to endothelial cells and diminishing inflammatory responses. As recently reviewed, physical exercise stimulates the expression of the anti-inflammatory molecules IL1-receptor antagonist and soluble TNF receptor as well as inducing antioxidant enzymes in tissues. 87 These receptor-based anti-inflammatory responses and antioxidant effects (reducing inflammatory responses to ROS) would complement the altered prostaglandin and leukotriene profiles produced by EPA treatment and should reduce the inflammatory response further than EPA treatment alone. By encouraging such lifestyle modifications in exposed individuals, the resulting anti-inflammatory effects may greatly reduce risk for pulmonary fibrosis and lung cancer in infectious (pulmonary) or mineral-exposed individuals. In light of the events of September 11, 2001 , in New York City, with thousands of tons of concrete dust (silica) being blown into the air and inhaled by many tens of thousands of individuals over a period of several days, these suggested prophylactic measures may be very important in reducing risk for future pulmonary disorders.
Such preventive paradigms may be important not only for preventing primary cancers but also for attenuating risk for the development of secondary cancers as a component of treatment paradigms. Only by integrating a variety of treatment paradigms that target all possible mechanisms that contribute to cancer can effective preventive measures be instituted. Although chemotherapy and radiation therapy target the cancer cells for eradication, they do not address any of the mechanisms that caused the cancer in the first place. The side effects of these therapies, very often chemical and oxygen radical-mediated tissue damage with concomitant inflammatory (and damaging) responses, can be very important causes of future secondary cancers in addition to the well-known debilitating effects they have on quality of life. The possibility exists that such preventive lifestyle changes as mentioned above also will be important in attenuating the side effects of cancer therapies and reducing risk for second cancers or recurrences of the primary cancer.
In conclusion, mechanisms of inflammation may be of paramount importance to both developing cancers and the detrimental effects of treating cancers. By using integrated measures to attenuate mechanisms of inflammatory-mediated risk, incidence of a variety of cancers (as well as some of the side effects of treating those cancers) could be reduced.
